Waters Corporation reported Q1 2026 revenue of $1.267 billion, surpassing guidance due to strong organic growth of 13% and contributions from its recent acquisition of Biosciences and Diagnostic Solutions. Adjusted EPS rose 20% to $2.70 despite a GAAP loss driven by acquisition-related charges. The company raised its full-year 2026 organic revenue growth guidance to 6.5%-8% and adjusted EPS guidance to $14.40-$14.60, reflecting confidence in continued momentum from new product launches and integration synergies. Waters expects sustained growth across its divisions and plans a seamless integration of acquired businesses to drive long-term success.
BioLineRx, a clinical-stage biopharmaceutical company, will release its Q1 2026 financial results on May 27, 2026. Analysts expect an earnings loss of $1.04 per share and revenue of $343,000, reflecting ongoing development costs typical for its growt...
Google Cloud Security used the Instruqt platform to train over 150 professionals on Agentic AI during the Google Next 2026 conference. Each participant worked in a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, ...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 practitioners on Agentic AI. Each participant received a dedicated Vertex AI environment to build their own AI agents hands-on, moving beyond slide-based demos. T...
At the 2026 Google Next conference, Google Cloud Security used the Instruqt platform to provide hands-on Agentic AI training to over 150 practitioners. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI a...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 professionals in agentic AI capabilities. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, moving...
